Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart bracelets could read the hidden signs of apathy in dementia

NCT ID NCT04865172

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study tests whether wearable sensors and caregiver questionnaires can capture the behavioral signs of apathy in people with dementia during daily life. Patients with Alzheimer's or frontotemporal dementia and their caregivers wear a sensor bracelet for 28 days, while caregivers answer weekly questions via a smartphone app. The goal is to see if these remote measurements can reliably track apathy-related behaviors like activity levels, sleep quality, and emotional arousal, potentially paving the way for a home-based monitoring tool.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remote monitoring with a wearable sensor bracelet and smartphone questionnaires
What this could lead to
If successful, this could lead to a tool for remotely tracking apathy in dementia patients, helping caregivers and clinicians monitor the condition from home.
What could go wrong
This is a small, early-stage study focused on measurement, not treatment. The findings may not generalize, and sensor data may not reliably reflect apathy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

44 people

The number who actually took part.

Started

May 2022

Finished

May 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

20 patient-caregiver dyads with patients suffering from behavioral variant front-temporal dementia, 20 patient-caregiver dyads with patients suffering from Alzheimer disease, 20 healthy control dyads

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for patients: 1. Diagnosis of bvFTD according to Rascovsky's international criteria for the bvFTD group / diagnosis of AD according to Dubois's international criteria for the AD group; 2. No evidence of any other cerebral pathology; 3. A Mini-Mental State Evaluation (MMSE) score superior or equal to 10 (to minimise the effect of confounding factors related to very severe cognitive impairment); 4. Aged between 40 and 85; 5. No evidence of any psychiatric condition and a Montgomery-Åsberg Depression Rating Scale (MADRS) score inferior to 20 (to avoid confusion between depression and apathy); 6. No evidence of excessive consumption of psychotropic drugs - for instance benzodiazepines, sleeping pills, etc. (due to their tranquilising effect); 7. No major physical disability disrupting mobility; 8. No heart pacemaker (which would compromise heart rate measuring). Inclusion Criteria for caregivers and partners of healthy control dyads: 1. Aged between 40 and 85; 2. No evidence of any psychiatric condition; 3. A MADRS score inferior to 20; 4. No evidence of excessive consumption of psychotropic drugs; 5. No major physical disability disrupting mobility; 6. No heart pacemaker. Exclusion Criteria: 1. Persons in detention by judicial or administrative decision 2. Person who is subject to a legal protection order 3. Person submitted to an exclusion period due to the participation to another research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease behavioral variant of frontotemporal dementia Pick disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Frontotemporal dementia, behavioral variant

Contacts and locations

Locations

  • ICM, Hôpital Salpêtrière

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.